📊 ANIK Key Takeaways
Is Anika Therapeutics, Inc. (ANIK) a Good Investment?
Anika Therapeutics exhibits strong balance sheet fundamentals with excellent liquidity (4.72x current ratio) and conservative leverage (0.17x debt/equity), but faces operational headwinds with negative operating margins (-9.8%) and declining revenue (-5.9% YoY). The company is generating positive free cash flow ($4.4M) despite net losses, suggesting operational improvements may be emerging, though profitability recovery remains uncertain.
Anika Therapeutics shows mixed fundamentals: a strong balance sheet, high liquidity, and positive free cash flow provide financial stability, but declining revenue and negative operating margins indicate the core business is not yet generating consistent profitable growth. The sharp improvement in net income is encouraging, but growth quality remains questionable until revenue stabilizes and operating leverage improves.
Why Buy Anika Therapeutics, Inc. Stock? ANIK Key Strengths
- Exceptional liquidity position with $57.5M cash and 4.72x current ratio provides significant financial flexibility
- Strong balance sheet with moderate leverage (0.17x D/E) and $143.5M stockholders' equity
- Positive free cash flow generation ($4.4M) despite GAAP losses indicates underlying operational cash generation
- Substantial gross margin of 56.6% demonstrates healthy product economics and pricing power
- Strong liquidity with a 4.72x current ratio and $57.48M in cash supports operational flexibility
- Low leverage with debt/equity of 0.17x limits balance-sheet risk
- Positive operating cash flow and free cash flow indicate the business is still generating cash despite accounting losses
ANIK Stock Risks: Anika Therapeutics, Inc. Investment Risks
- Persistent profitability challenges with negative operating (-9.8%) and net margins (-9.6%)
- Revenue contraction of 5.9% YoY signals demand pressure or market share loss
- Operating losses of $11.1M are not offset by strong cash generation, suggesting one-time charges or non-cash impacts
- Medical devices sector experiencing competitive pressure; company's turnaround path unclear
- Revenue declined 5.9% year over year, signaling weak top-line momentum
- Negative operating and net margins show the company has not restored sustainable profitability
- Returns on equity and assets remain negative, reflecting inefficient capital utilization
Key Metrics to Watch
- Revenue growth trajectory and segment performance - must stabilize and return to growth
- Operating margin progression - path to positive EBIT is critical for valuation
- Cash burn rate and free cash flow sustainability - ensure runway extends beyond turnaround period
- Gross margin stability - monitor for pricing pressure or unfavorable product mix shifts
- Revenue growth recovery and product-level sales mix
- Operating margin and free cash flow consistency
Anika Therapeutics, Inc. (ANIK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.72x current ratio provides a solid financial cushion.
ANIK Profit Margin, ROE & Profitability Analysis
ANIK vs Healthcare Sector: How Anika Therapeutics, Inc. Compares
How Anika Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Anika Therapeutics, Inc. Stock Overvalued? ANIK Valuation Analysis 2026
Based on fundamental analysis, Anika Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Anika Therapeutics, Inc. Balance Sheet: ANIK Debt, Cash & Liquidity
ANIK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Anika Therapeutics, Inc.'s revenue has declined by 18% over the 5-year period, indicating business contraction. The most recent EPS of $-5.64 indicates the company is currently unprofitable.
ANIK Revenue Growth, EPS Growth & YoY Performance
ANIK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $27.8M | -$88.0K | $-0.16 |
| Q2 2025 | $28.2M | -$88.0K | $0.00 |
| Q1 2025 | $26.2M | -$4.5M | $-0.31 |
| Q3 2024 | $38.8M | -$88.0K | $-0.45 |
| Q2 2024 | $41.9M | -$88.0K | $-0.01 |
| Q1 2024 | $37.9M | -$4.5M | $-0.31 |
| Q3 2023 | $40.3M | -$2.7M | $-0.29 |
| Q2 2023 | $39.7M | -$2.7M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Anika Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ANIK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Anika Therapeutics, Inc. (CIK: 0000898437)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANIK
What is the AI rating for ANIK?
Anika Therapeutics, Inc. (ANIK) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANIK's key strengths?
Claude: Exceptional liquidity position with $57.5M cash and 4.72x current ratio provides significant financial flexibility. Strong balance sheet with moderate leverage (0.17x D/E) and $143.5M stockholders' equity. ChatGPT: Strong liquidity with a 4.72x current ratio and $57.48M in cash supports operational flexibility. Low leverage with debt/equity of 0.17x limits balance-sheet risk.
What are the risks of investing in ANIK?
Claude: Persistent profitability challenges with negative operating (-9.8%) and net margins (-9.6%). Revenue contraction of 5.9% YoY signals demand pressure or market share loss. ChatGPT: Revenue declined 5.9% year over year, signaling weak top-line momentum. Negative operating and net margins show the company has not restored sustainable profitability.
What is ANIK's revenue and growth?
Anika Therapeutics, Inc. reported revenue of $112.8M.
Does ANIK pay dividends?
Anika Therapeutics, Inc. does not currently pay dividends.
Where can I find ANIK SEC filings?
Official SEC filings for Anika Therapeutics, Inc. (CIK: 0000898437) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANIK's EPS?
Anika Therapeutics, Inc. has a diluted EPS of $-0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANIK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Anika Therapeutics, Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANIK stock overvalued or undervalued?
Valuation metrics for ANIK: ROE of -7.6% (sector avg: 15%), net margin of -9.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANIK stock in 2026?
Our dual AI analysis gives Anika Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANIK's free cash flow?
Anika Therapeutics, Inc.'s operating cash flow is $11.2M, with capital expenditures of $6.8M. FCF margin is 3.9%.
How does ANIK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.6% (avg: 12%), ROE -7.6% (avg: 15%), current ratio 4.72 (avg: 2).